Phase Trial D Status Prime Boost 1 Boost 2 Strategy Location HVTN 117 VA Ongoing Ad26.Mos.HV Ad26.Mos4.HV gp140 C Rwanda C89220HPX200 4 Trivalent Vector -, b HVTN 704 AMP Ongoing VRC-HVMAB0 60-00-AB Passive, Peru, Brazil 01--0079 Completed VRC4302 04/400-003-04 Completed APL 400-003 GENEVAX-HV 10-1074 Ongoing 10-1074 Passive Germany, 87-114 Completed gp160 Vaccine (mmuno-ag) 96--0050 Completed APL 400-003 GENEVAX-HV / ACTG 326; PACTG 326 Completed ALVAC vcp1452 ADSVAX B/B Ad26.ENVA.01 Completed Ad26.EnvA-01 Ad26.ENVA.01 Ongoing Ad26.EnvA-01 Mucosal/PCAV D003 Ad5HVR48.EN Ongoing Ad5HVR48.EN VA.01 VA.01 ANRS VAC 01 Completed ALVAC vcp125 gp160 Vaccine France ANRS VAC 02 Completed rgp 160 + peptide V3 ANRS VAC 02 ANRS VAC 03 Completed ALVAC-HV (mmuno-ag) CLTB-36 (gp24e-v3 MN) France France
ANRS VAC 04 Completed LPO-6 France ANRS VAC 04 Completed LPO-6 France bis ANRS VAC 05 Completed ALVAC vcp125 ALVAC (vcp rage), Viral France ANRS VAC 06 Completed ALVAC vcp125 ALVAC (vcp rage), Viral ANRS VAC 07 Completed ALVAC vcp300 ANRS VAC 08 Completed ALVAC-HV ANRS VAC 09 Completed ALVAC-HV ALVAC vcp300 LPO-6, Viral, France France France France ANRS VAC 09 Completed LPO-6 France bis ANRS VAC 10 Completed ALVAC LPO-6T LPO-5 France vcp1452, ANRS VAC 12 Completed LPHV1 France ANRS VAC 14 Terminated gp160 MN/LA France ANRS VAC 16 Completed LPHV1 France ANRS VAC 17 Completed LPO-6 France ANRS VAC 18 Completed LPO-5 France APL 400-003RX101 Completed APL 400-003 GENEVAX-HV AVEG 002 Completed HVAC-1e gp160 MN/LA AVEG 002A Completed HVAC-1e
AVEG 002B Completed HVAC-1e VaxSyn gp160 Vaccine (MicroGeneSys) AVEG 003 Completed VaxSyn gp160 Vaccine (MicroGeneSys) AVEG 003A Completed VaxSyn gp160 Vaccine (MicroGeneSys) AVEG 003B Completed VaxSyn gp160 Vaccine (MicroGeneSys) AVEG 004 Completed gp160 Vaccine (mmuno-ag) AVEG 004A Completed gp160 Vaccine (mmuno-ag) AVEG 004B Completed gp160 Vaccine (mmuno-ag) AVEG 005A/B Completed Env 2-3 AVEG 005C Completed Env 2-3 AVEG 006X; Completed MN rgp120 VEU 006 AVEG 007A/B Completed rgp120/hv-1 AVEG 007C Completed rgp120/hv-1 AVEG 008 Completed HVAC-1e AVEG 009 Completed MN rgp120 AVEG 010 Completed HVAC-1e rgp120/hv-1 MN rgp120, AVEG 011 Completed UB HV-1 Peptide
mmunogen, Multivalent AVEG 012A/B Completed ALVAC vcp125 AVEG 013A Completed gp160 Vaccine (mmuno-ag) AVEG 013B Completed gp160 Vaccine (mmuno-ag) AVEG 014A/B Completed TBC-3B AVEG 014C Completed TBC-3B MN rgp120 AVEG 015 Completed rgp120/hv-1 AVEG 016 Completed MN rgp120 AVEG 016A Completed MN rgp120 AVEG 016B Completed MN rgp120 AVEG 017 Completed UB HV-1 Peptide Vaccine, Microparticulate Monovalent AVEG 018 Completed UB HV-1 Peptide Vaccine, Microparticulate Monovalent AVEG 019 Completed p17/p24:ty- Virus Like VLP Particles AVEG 020 Completed gp120 C4-V3 AVEG 021 Completed P3C541b Lipopeptide AVEG 022 Completed ALVAC-HV
AVEG 022A Completed ALVAC-HV AVEG 023 Completed UB HV-1 Peptide mmunogen, Multivalent rgp120/hv-1 AVEG 024 Completed rgp120/hv-1 AVEG 026 Completed ALVAC vcp300 rgp120/hv-1 AVEG 027 Completed ALVAC-HV AVEG 028 Completed Salmonella typhi CVD 908-HV-1 LA gp 120 AVEG 029 Completed ALVAC-HV MN rgp120 rgp120/hv-1 AVEG 031 Completed APL 400-047 ALVAC-HV AVEG 032 Completed ALVAC-HV AVEG 033 Completed ALVAC-HV AVEG 034/034A Completed ALVAC vcp1433 rgp120/hv-1 ALVAC vcp1452 ALVAC-HV Bacterium + gp 120,, Viral, Viral,
AVEG 036 Completed MN rgp120 ADSVAX B/E, AVEG 038 Completed ALVAC-HV AVEG 201 Completed rgp120/hv-1 AVEG Completed ALVAC-HV 202/HVNET 014 MN rgp120 rgp120/hv-1, / C060301 Completed GTU-MultiHV Finland C86P1 Completed HV gp140 ZM96 United Kingdom Cervico-vaginal Completed CN54gp140 United Kingdom CN54gp140-hs p70 Conjugate Vaccine (TL01) CM235 and SF2gp120 CM235gp120 and SF2gp120 Completed Completed CM235 (ThaiE) gp120 plus SF2(B) gp120 CM235 (ThaiE) gp120 plus SF2(B) gp120 rgp120/hv-1 rgp120/hv-1, Thailand, Thailand CombiHVvac ( KombiVChvak) Scheduled CombiHVvac Virus Like Particles Russian Federation CRC282 Completed P2G12 Passive United Kingdom CRO2049/ CUT*HVAC001 Ongoing GTU-MultiHV United Kingdom CUTHVAC002 Ongoing -C CN54ENV CN54gp140, United Kingdom DCVax-001 Completed DCVax-001-4 Completed -4 Russian
Federation DP6?001 Completed DP6?001 DP6 protein, DVP-1 Closed to follow-envdnup EnvPro PolyEnv1,, EN41-UGR7C Completed EN41-UGR7C United Kingdom Env Closed to follow-envdnup EnvPro Completed EnvPro EuroNeut41 Completed EN41-FPA2 United Kingdom EV01 Completed NYVAC-C Switzerland, United Kingdom / EV02 (EuroVacc 02) Completed -C NYVAC-C, Viral Switzerland, United Kingdom / EV03/ANRSVA Completed -C NYVAC-C, Viral France, C20 Germany, Switzerland, Extention HVTN 073E/SAAV 102 United Kingdom Completed Sub C gp140 / F4/AS01 Completed F4/AS01 Belgium FT Biotech Completed GTU-Nef Finland Guangxi CDC Completed Chinese China vaccine HGP-30 memory responses Completed HGP-30 HV-CORE002 Completed ChAdV63.HVc onsv MVA.HVconsv psg2.hvconsv, HV-POL-001 Completed MVA-mBN32 United Kingdom Germany
HVS 01 Completed HVS- Sweden HVS 02 Completed MVA-CMDR Sweden / HVS 03 Closed to follow-hvs-dnup MVA-CMDR, Viral Tanzania HVS 05 Completed HVS- MVA-CMDR, Viral Sweden / HVS06 Completed HVS- MVA-CMDR, Viral Tanzania HVS07 Completed HVS- MVA-CMDR, Viral Sweden HVNET 007 Completed ALVAC-HV Uganda HVNET 026 Completed ALVAC vcp1452 MN rgp120 Brazil, Haiti, Peru, Trinidad & Tobago HPTN 027 Completed ALVAC-HV Uganda vcp1521 HVRF-380-131 004 Completed Vichrepol Russian Federation HVTN 039 Completed ALVAC vcp1452 HVTN 040 Completed AVX101 Alphavirus HVTN 041 Completed rgp120w61d / HVTN 042 / Completed ALVAC LPO-5 ANRS VAC 19 vcp1452 HVTN 044 Completed VRC-HV0 09-00-VP HVTN 045 Completed pga2/js7 HVTN 048 Completed EP HV-1090 Botswana, HVTN 049 Completed Gag and Env /PLG Oligomeric gp140/mf59,
HVTN 050/Merck 018 Terminated microparticles MRKAd5 HV-1 gag Brazil, Dominican Republic, Haiti, Malawi, Peru, Thailand, b HVTN 052 Completed VRC-HV0 09-00-VP HVTN 054 Completed VRC-HVADV0 14-00-VP HVTN 055 Completed TBC-M335 TBC-M358 TBC-F357 Brazil,, Viral, HVTN 056 Completed MEP HVTN 057 Completed VRC-HV0 VRC-HVADV0, Viral 09-00-VP 14-00-VP Vector - HVTN 059 Completed AVX101 Alphavirus Botswana, HVTN 060 Completed HV-1 gag Thailand, HVTN 063 Completed HV-1 gag HVTN 064 Completed EP HV-1043 EP HV-1090, HVTN 065 Completed pga2/js7 MVA/HV62, Viral HVTN 067 Completed EP-1233 MVA-mBN32, Viral a HVTN 068 Completed VRC-HVADV0 VRC-HVADV0 14-00-VP 14-00-VP b HVTN 069 Completed VRC-HV0 09-00-VP VRC-HVADV0 14-00-VP Vector -, Viral Vector -
HVTN 070 Completed PENNVAX-B b HVTN 071 Terminated MRKAd5 HV-1 gag b HVTN 072 Completed VRC-HV0 VRC-HVADV0 VRC-HVADV0, Viral 44-00-VP 27-00-VP 38-00-VP Vector -, HVTN 073 Completed SAAV -C2 SAAV MVA-C, Viral HVTN 076 Ongoing VRC-HV0 VRC-HVADV0, Viral 16-00-VP b HVTN 077 Completed VRC-HVADV0 27-00-VP 14-00-VP VRC-HVADV0 38-00-VP b HVTN 078 Completed NYVAC-B VRC-HVADV0 38-00-VP VRC-HV0 44-00-VP Vector - Vector -,, Viral Vector - HVTN 080 Completed PENNVAX-B b HVTN 082 Completed VRC-HV0 VRC-HVADV0, Viral 16-00-VP 14-00-VP Vector - HVTN 083 Ongoing VRC-HVADV0 VRC-HVADV0 VRC-HVADV0 38-00-VP 52-00-VP 27-00-VP HVTN 084 Ongoing VRC-HVADV0 54-00-VP b HVTN 085 Ongoing VRC-HVADV0 14-00-VP VRC-HVADV0 14-00-VP VRC-HVADV0 38-00-VP VRC-HVADV0 52-00-VP Vector -, Vector - Vector -, Switzerland Peru, Brazil,, Swaziland, Peru, Brazil, Switzerland
HVTN 086, SAAV 103 Ongoing SAAV MVA-C SAAV -C2 Oligomeric gp140/mf59 HVTN 087 Completed HV-MAG VSV-ndiana HV gag vaccine HVTN 088 Completed Oligomeric gp140/mf59 HVTN 090 Completed VSV-ndiana HV gag vaccine HVTN 092 Ongoing -HV- PT123 NYVAC-HV- PT1 NYVAC-HV- PT4,,, Viral Vector - Replicating Replicating, Viral, HVTN 094 Completed GEO-D03 MVA/HV62, Viral HVTN 096 Completed -HV- NYVAC-HV- NYVAC-HV- PT123 PT1 PT4, Viral, South Africa, Switzerland Switzerland HVTN 097 Ongoing ALVAC-HV ADSVAX B/E South Africa vcp1521 HVTN 098 Ongoing PENNVAX-GP / HVTN 100 Ongoing ALVAC-HV-C (vcp2438) Bivalent Subtype C South Africa HVTN 101 Scheduled -HV- PT123 HVTN 102 Withdrawn -HV- PT123 HVTN 104 Completed VRC-HVMAB0 60-00-AB gp120/mf59 NYVAC-HV- PT1 NYVAC-HV- PT1 ADSVAX B/E, ADSVAX B/E, Viral, Passive
b HVTN 105 Completed ADSVAX B/E -HV- PT123 HVTN 106 Ongoing Nat-B env Mosaic Env / HVTN 108 Ongoing -HV- PT123 Bivalent Subtype C gp120/as01b MVA-CMDR Bivalent Subtype C gp120/mf59,,,,, HVTN 110 Ongoing Ad4-mgag Ad4-EnvC150 ADSVAX B/E Replicating, Replicating, HVTN 111 Ongoing -HV- PT123 /MF59 vaccine, HVTN 112 Ongoing HV-1 nef/tat/vif, rvsv envc, Viral env p vaccine Vector - Replicating HVTN 114; Scheduled ADSVAX B/E MVA/HV62, Viral GOVX-B11 HVTN 116 Ongoing VRC-HVMAB0 VRCHVMAB08 Passive 60-00-AB 0-00-AB, Passive HVTN 118 PCAVD-012 Ongoing Ad26.Mos4.HV gp140 C Mosaic gp140,, HVTN 203 Completed ALVAC vcp1452 ADSVAX B/B, HVTN 204 Closed to follow-vrc-hvup VRC-HVADV0, Viral 16-00-VP 14-00-VP Vector - a HVTN 205 Completed pga2/js7 MVA/HV62, Viral Zambia, Tanzania, South Africa, Kenya, Rwanda Peru,
b HVTN 502/Merck 023 (Step Study) Terminated MRKAd5 HV-1 gag/pol/nef b HVTN 503 (Phambili) Terminated MRKAd5 HV-1 gag/pol/nef b HVTN 505 Terminated VRC-HV0 VRC-HVADV0 16-00-VP 14-00-VP HVTN 702 Ongoing ALVAC-HV-C Bivalent (vcp2438) Subtype C gp120/mf59 b HVTN 703 AMP Ongoing VRC-HVMAB0 60-00-AB, Viral Vector - Passive Australia, Canada, Dominican Republic, Haiti, Peru, Puerto Rico, South Africa South Africa Kenya, Malawi, Mozambique, Tanzania, Botswana Peru, HVTN 908 Completed pga2/js7 MVA/HV62, Viral AV 001 Completed.HVA United Kingdom AV 002 Completed.HVA Kenya AV 003 Completed MVA.HVA United Kingdom AV 004 Completed MVA.HVA Kenya AV 005 Completed.HVA MVA.HVA, Viral United Kingdom / AV 006 Completed.HVA MVA.HVA, Viral United Kingdom AV 008 Completed MVA.HVA Kenya AV 009 Completed.HVA MVA.HVA, Viral Uganda
a AV 010 Completed.HVA MVA.HVA, Viral AV 011 Completed MVA.HVA AV 016 Completed MVA.HVA.HVA MVA.HVA,, Viral AV A001 Completed tgaac09 A denoassociated Virus AV A002 Completed tgaac09 A denoassociated Virus Kenya, United Kingdom Switzerland, United Kingdom United Kingdom Belgium, Germany, ndia Uganda, Zambia AV A003 Ongoing AAV1-PG9 Vectored mmu United Kingdom noprophylaxis AV B001 Completed Ad35-GRN/EN Ad35-GRN/EN V V AV B002 Completed Adjuvanted GSK investigational HV vaccine formulation 1 Adjuvanted GSK investigational HV vaccine formulation 2 Ad35-GRN Vector -,, AV B003 Completed Ad26.EnvA-01 Ad35-ENV Vector - AV B004 Completed HV-MAG Ad35-GRN/EN V, Viral Vector - AV C001 Completed ADVAX AV C002 Completed ADMVA Kenya, Uganda, Zambia Kenya, Rwanda, South Africa, Kenya, Rwanda, Uganda
AV C003 Completed ADMVA AV Completed ADVAX C004/DHO-614 AV D001 Completed TBC-M4 ndia / AV N004 HV- CORE 004 Completed Ad35-GRN MVA.HVconsv psg2.hvconsv psg2.hvconsv,, AV P001 Completed ADVAX TBC-M4, Viral AV P002 Completed ADVAX TBC-M4, Viral AV R001 Completed rcad26.mos1. HVEnv Replicating AV S001 Completed SeV-G Ad35-GRN Replicating, AV T001 Ongoing PGT121 Passive AV V001 Completed VRC-HV0 VRC-HVADV0, Viral 16-00-VP 14-00-VP Vector - AV V002 Withdrawn VRC-HV0 VRC-HVADV0, Viral 16-00-VP 14-00-VP Vector - DEA EV06 Completed -HV- PT123 HV01 Ongoing Full-Length Single Chain (FLSC) Kenya ndia United Kingdom Kenya, United Kingdom, Rwanda Kenya, Rwanda Kenya, Rwanda, Uganda, Zambia ADSVAX B/E, Uganda
MPAACT P1112 Ongoing VRC-HVMAB0 60-00-AB Passive PCAVD006 Completed MVA mosaic PCAVD008 Completed Trimeric gp140 / PCAVD009 Ongoing Ad26.Mos.HV Trivalent gp140 C MVA mosaic,,, Puerto Rico, South Africa, Rwanda, Thailand, Uganda PCAVD010 Ongoing Ad26.Mos.HV gp140 C Trivalent, SS P-001 Completed Tat vaccine taly SS P-002 Completed Tat vaccine HV-1 delta-v2 Env vaccine, taly LFn-p24 Completed LFn-p24 vaccine MCA-0835 Completed 3BNC117 Passive Germany, Merck Completed Ad-5 HV-1 gag MRKAd5 HV-1 V520-007 (Merck) gag Vector - MRC V001 Completed rgp120w61d United Kingdom MRK Ad5 Completed Ad-5 HV-1 gag (Merck) MRKAd5 + Completed MRKAd5 HV-1 ALVAC-HV ALVAC gag Mucovac2 Completed CN54gp140 United Kingdom MV1-F4 Completed Measles Vector Belgium - GSK Replicating MYM-V101 Completed Virosome-Gp41 Belgium / NCHECR-AE1 Completed phs-hv-ae rfpv-hv-ae, Viral Thailand
up Ongoing Ad4-mgag Ad4-EnvC150 Replicating, Replicating PXVX- HV-100-001 PACTG 230 Completed ADSVAX B/E rgp120/hv-1, b PAVE100 Withdrawn VRC-HV0 VRC-HVADV0, Viral 16-00-VP 14-00-VP Vector - PEACH-04 Ongoing ChAdV63.HVc MVA.HVconsv United Kingdom onsv PedVacc001 & PedVacc002 Completed MVA.HVA Gambia, Kenya PolyEnv1 Closed to follow-polyenv1 RSVAC02 Completed MVA-B RisVac02 boost Scheduled MVA-B RV 124 Completed ALVAC-HV gp160mn/la-2 / RV 132 Completed ALVAC-HV vcp1521 gp160 rgp120/hv-1 THO23/LA-DD, Spain Spain Thailand / RV 135 Completed ALVAC-HV gp120 C4-V3 Thailand vcp1521 RV 138; B011 Completed ALVAC-HV RV 144 Completed ALVAC-HV ADSVAX Thailand vcp1521 gp120 B/E RV 151 / WRAR 984 Completed LFn-p24
RV 156 Completed VRC-HV0 09-00-VP RV 156A Completed VRC-HV0 VRC-HVADV0, Viral 09-00-VP 14-00-VP Vector - RV 158 Completed MVA-CMDR / RV 172 Completed VRC-HV0 VRC-HVADV0, Viral 16-00-VP 14-00-VP Vector - Uganda Uganda Thailand, Kenya, Tanzania, Uganda RV 305 Ongoing ALVAC-HV ADSVAX B/E Thailand vcp1521 RV 306 Ongoing ALVAC-HV ADSVAX B/E Thailand vcp1521 RV 328 Ongoing ADSVAX B/E Thailand RV 365 Completed MVA-CMDR RV262 Completed Pennvax-G MVA-CMDR, Viral Kenya, Tanzania, Uganda, SG06RS02 Terminated HV gp140 United Kingdom ZM96 TAB9 Completed TAB9 Cuba TaMoVac Completed HVS- MVA-CMDR, Viral Tanzania, Mozambique TAMOVAC-01- MZ Completed HVS- MVA-CMDR, Viral Mozambique Tiantan vacciniacompleted Chinese Tiantan vaccinia, Viral China HV Vaccine Vector - Tiantan vaccinia HV Vaccine and Replicating Completed Chinese Tiantan vaccinia, Viral Vector - Replicating TMB-108 Completed balizumab Passive China
/ UB HV-1 MN China UB HV-1MN octameric - Australia study Completed Completed UB HV-1 Peptide mmunogen, Multivalent UB HV-1 Peptide mmunogen, Multivalent / UB V106 Completed UB HV-1 Peptide Vaccine, Microparticulate Monovalent UCLA MG-001 Completed TBC-3B UCLA MG-003 Completed ALVAC-HV UKHVCSpoke0 03 Completed - CN54ENV and ZM96GPN MVA-C CN54gp140, Viral, China Australia United Kingdom V24P1 Completed HV p24/mf59 Vaccine V3-MAPS Completed V3-MAPS Brazil, China, Australia, Thailand, V520-016 Completed MRKAd5 HV-1 gag/pol/nef V520-027 Terminated MRKAd5 HV-1 gag/pol/nef MRKAd5 HV-1 gag/pol/nef MRKAd5 HV-1 gag/pol/nef Vector -, V526-001 Completed MRKAd5 HV-1 MRKAd6 MRKAd5+6
MRKAd5 and MRKAd6 HV-1 Trigene Vaccines gag/pol/nef HV-1 Vector -, / VAX 002 Completed ADSVAX B/B ADSVAX B/E, VAX 003 Completed ADSVAX B/E Thailand VAX 004 Completed ADSVAX B/B Canada, Netherlands, Puerto Rico, VRC 004 Completed VRC-HV0 (03--0022) 09-00-VP VRC 006 Completed VRC-HVADV0 (04--0172) 14-00-VP VRC 007 Completed VRC-HV0 (04--0254) 16-00-VP VRC 008 Completed VRC-HV0 VRC-HVADV0, Viral (05--0148) 16-00-VP 14-00-VP Vector - VRC 009 Completed VRC-HV0 VRC-HVADV0, Viral (05--0081) 09-00-VP 14-00-VP Vector - VRC 010 Completed VRC-HVADV0 (05--0140) 14-00-VP VRC Completed VRC-HV0 VRC-HVADV0, Viral 011(06--0149) 16-00-VP 14-00-VP Vector - VRC 012 Completed VRC-HVADV0 VRC-HVADV0 (07--0167) 27-00-VP 38-00-VP Vector - VRC 015 (08--0171) Completed VRC-HVADV0 14-00-VP b VRC 016 Completed VRC-HV0 VRC-HVADV0, Viral 16-00-VP 14-00-VP Vector - VRC 602 Completed VRC-HVMAB0 Passive 60-00-AB VRC 605 Ongoing VRC-HVMAB0 Passive
Powered by TCPDF (www.tcpdf.org) 75-00-AB VRC 607 Ongoing VRCHVMAB08 Passive 0-00-AB VRC01LS Ongoing VRCHVMAB08 Passive 0-00-AB / VR01 Completed MVA-B LPO-5 GTU-MultiHV France, X001 Completed CN54gp140 United Kingdom